Rephonic
Artwork for CCO Oncology Podcast

CCO Oncology Podcast

Clinical Care Options
Chronic Lymphocytic Leukemia
BTK Inhibitors
Non-Small Cell Lung Cancer
Mantle Cell Lymphoma
Her3-Targeted Therapy
CAR T-Cell Therapy
Clinical Trials
Triangle Study
Pyrtobrutinib
SHINE Trial
NCCN Guidelines
ASCO Annual Meeting
AML Treatment Regimens
Acute Myelogenous Leukemia
Small Lymphocytic Lymphoma
Gold Standard Therapy
Myelofibrosis
Palliative Care
Oral Sirds
Targeted Therapy

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

PublishesTwice weeklyEpisodes211Founded5 years ago
Number of ListenersCategories
Health & FitnessCoursesMedicineEducation

Listen to this Podcast

Artwork for CCO Oncology Podcast

Latest Episodes

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/... more

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic test... more

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:

• Brie... more

YouTube

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clini... more

YouTube

Key Facts

Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
NEJM This Week
NEJM This WeekNEJM Group
The Journal.
The Journal.The Wall Street Journal & Spotify Studios
OncLive® On Air
OncLive® On AirOncLive® On Air
ASCO Daily News
ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)

Recent Guests

Dr. Kelly Romo
Healthcare professional specializing in oncology at Blue Cross and Blue Shield of Michigan.
Blue Cross and Blue Shield of Michigan
Episode: Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
Dr. Shauna Kraft
Pharmacist and academic at the University of Michigan College of Pharmacy.
University of Michigan
Episode: Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
Eunice Wang
Oncologist from Roswell Park
Roswell Park Comprehensive Cancer Center
Episode: A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
Eytan Stein
Oncologist
Episode: A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
Joseph Franses
Assistant professor of medicine at the University of Chicago in the section of Hematology-Oncology.
University of Chicago
Episode: Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Neehar Parikh
Associate professor in the Division of Gastroenterology & Hepatology at the University of Michigan.
University of Michigan
Episode: Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Mark Yarchoan
Associate Professor of Medical Oncology at the Sidney Kimmel Cancer Institute at Johns Hopkins University.
Johns Hopkins University
Episode: Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
Dr. Sara Hurvitz
Professor of Medicine, Smith Family Endowed Chair in Women's Health at the University of Washington, and Senior Vice President of the Clinical Research Division at the Fred Hutch Cancer Center.
Fred Hutch Cancer Center, University of Washington
Episode: Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
Ms. La-Urshalar Brock
Family Nurse Practitioner and a Certified Nurse Midwife at Winship Cancer Institute at Emory University.
Emory University
Episode: Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#142
United States/Education/Courses
Apple Podcasts
#204
Canada/Education/Courses
Apple Podcasts
#189
Australia/Education/Courses
Apple Podcasts
#30
Denmark/Education/Courses
Apple Podcasts
#36
Chile/Education/Courses
Apple Podcasts
#41
Singapore/Education/Courses
Apple Podcasts
#41
Japan/Education/Courses
Apple Podcasts
#51
New Zealand/Education/Courses
Apple Podcasts
#56
Sweden/Education/Courses
Apple Podcasts
#83
Israel/Education/Courses
Apple Podcasts
#85
Argentina/Education/Courses
Apple Podcasts
#101
Taiwan/Education/Courses
Apple Podcasts
#105
Netherlands/Education/Courses
Apple Podcasts
#131
Brazil/Education/Courses
Apple Podcasts
#202
South Korea/Education/Courses
Apple Podcasts
#206
South Africa/Education/Courses
Apple Podcasts
#239
Austria/Education/Courses

Talking Points

Recent interactions between the hosts and their guests.

Current Considerations for Adverse Event Management With HER3-Directed Agents
Q: What is one thing that you would like community practitioners to know about HER3-targeted therapy?
There is currently no HER3-targeted therapy or ADC that is approved, but it's an exciting time with new drugs showing promising efficacy signals.
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Q: What are you going to do in your practice with the cervical cancer data?
Dr. Fujiwara indicated he would likely use the interlaced regimen, probably in combination with PEMBRO, once the A18 result is approved for regulatory agents.
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Q: How do you apply these results in your practice?
Dr. Slomovitz suggests that it's early to incorporate the new data based on Dervalumab and Tesolizumab, but acknowledges that both Pembrolizumab and Dostarlumab are active agents and can be interchangeable in practice.
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Q: Are you guys using a lot of IBSSM?
The speakers indicate that it has become standard in their practice, highlighting the importance of NGS mutation knowledge.
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Q: What is the uptake of the IPSSM in your centers?
The IPSSM is increasingly important, showing substantial differences in patient stratification based on molecular mutations.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About CCO Oncology Podcast

What is CCO Oncology Podcast about and what kind of topics does it cover?

This series focuses on the latest developments in cancer treatment and patient care, offering insights from leading experts in the field. Episodes tackle a wide range of topics, from emerging therapies and clinical trial results to practical strategies for managing patient care across various cancer types, including both solid tumors and hematologic malignancies. The conversations not only highlight current research but also emphasize the importance of personalized approaches in cancer therapy, patient education, and evolving treatment paradigms. Special attention is given to developments in areas like bispecific antibodies, immunotherapy, and treatment options tailored to specific cancer types, providing listeners with valuable information... more

Where can I find podcast stats for CCO Oncology Podcast?

Rephonic provides a wide range of podcast stats for CCO Oncology Podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to CCO Oncology Podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does CCO Oncology Podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for CCO Oncology Podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for CCO Oncology Podcast?

Rephonic provides comprehensive predictive audience data for CCO Oncology Podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does CCO Oncology Podcast have?

To see how many followers or subscribers CCO Oncology Podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to CCO Oncology Podcast?

These podcasts share a similar audience with CCO Oncology Podcast:

1. Two Onc Docs
2. NEJM This Week
3. The Journal.
4. OncLive® On Air
5. ASCO Daily News

How many episodes of CCO Oncology Podcast are there?

CCO Oncology Podcast launched 5 years ago and published 211 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact CCO Oncology Podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for CCO Oncology Podcast?

Rephonic pulls ratings and reviews for CCO Oncology Podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for CCO Oncology Podcast?

Rephonic provides full transcripts for episodes of CCO Oncology Podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on CCO Oncology Podcast?

Recent guests on CCO Oncology Podcast include:

1. Dr. Kelly Romo
2. Dr. Shauna Kraft
3. Eunice Wang
4. Eytan Stein
5. Joseph Franses
6. Neehar Parikh
7. Mark Yarchoan
8. Dr. Sara Hurvitz

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days